Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 1/20 | 0.37 |
| ▸ | HTR2C | P28335 | 1/20 | 0.37 |
| ▸ | HTR2B | P41595 | 1/20 | 0.37 |
| ▸ | PLAU | P00749 | 1/20 | 0.36 |
| ▸ | IDH1 | O75874 | 6/20 | 0.36 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.34 |
| ▸ | GSK3B | P49841 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4183810 | 0.81 | GSK3B (0.34) | PLAUIDH1ADRA1AGSK3B | |
| SCHEMBL15529909 | 0.79 | IDH1 (0.39) | HTR2AHTR2CHTR2BIDH1ADRA1A | |
| SCHEMBL8039039 | 0.79 | GSK3B (0.39) | HTR2AHTR2CHTR2BIDH1ADRA1A | |
| SCHEMBL16700662 | 0.76 | IDH1 (0.40) | HTR2AHTR2CHTR2BIDH1 | |
| SCHEMBL21905591 | 0.76 | IDH1 (0.40) | IDH1 | |
| SCHEMBL8325895 | 0.75 | DRD2 (0.38) | HTR2AHTR2CHTR2BIDH1GSK3B | |
| SCHEMBL28153638 | 0.75 | IDH1 (0.36) | HTR2AHTR2CHTR2BIDH1ADRA1A | |
| SCHEMBL18067769 | 0.75 | IDH1 (0.36) | HTR2AHTR2CHTR2BIDH1ADRA1A | |
| SCHEMBL18068274 | 0.75 | PDPK1 (0.38) | HTR2AHTR2CHTR2BIDH1ADRA1A | |
| SCHEMBL22509084 | 0.73 | ANPEP (0.42) | IDH1GSK3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 94 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150141877-A1 | LED AND SHOCKWAVE THERAPY FOR TATTOO REMOVAL | INREXREM INC. (US) | 2015-05-21 | — | — | US | claimed |
| US-20140276246-A1 | SYSTEM AND METHOD FOR TATTOO REMOVAL | InrexRem | 2014-09-18 | — | — | US | claimed |
| EP-1651190-B1 | FORMULATIONS CONTAINING AN IMMUNE RESPONSE MODIFIER | 3M INNOVATIVE PROPERTIES CO (US) | 2012-09-19 | — | — | EP | claimed |
| US-7375180-B2 | Methods and compositions related to IRM compounds and Toll-like receptor 8 | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2008-05-20 | — | — | US | claimed |
| EP-1592302-A4 | METHODS AND COMPOSITIONS RELATED TO IRM COMPOUNDS AND TOLL-LIKE RECEPTOR 8 | 3M INNOVATIVE PROPERTIES CO (US) | 2007-04-25 | — | — | EP | claimed |
| US-7179253-B2 | Method of tattoo removal | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2007-02-20 | — | — | US | claimed |
| WO-2006130399-A2 | THERAPEUTIC COMBINATIONS AND METHODS INCLUDING IRM COMPOUNDS | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2006-12-07 | — | — | WO | claimed |
| EP-1603476-A2 | METHOD OF TATTOO REMOVAL | 3M Innovative Properties Company (US) | 2005-12-14 | — | — | EP | claimed |
| EP-1592302-A2 | METHODS AND COMPOSITIONS RELATED TO IRM COMPOUNDS AND TOLL-LIKE RECEPTOR 8 | 3M Innovative Properties Company (US) | 2005-11-09 | — | — | EP | claimed |
| US-20050226878-A1 | Therapeutic combinations and methods including IRM compounds | 3M INNOVATIVE PROPERTIES COMPANY | 2005-10-13 | — | — | US | claimed |
| WO-2004080292-A2 | METHOD OF TATTOO REMOVAL | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2004-09-23 | — | — | WO | claimed |
| US-20040181211-A1 | Method of tattoo removal | 3M INNOVATIVE PROPERTIES COMPANY | 2004-09-16 | — | — | US | claimed |
| WO-2004071459-A2 | METHODS AND COMPOSITIONS RELATED TO IRM COMPOUNDS AND TOLL-LIKE RECEPTOR 8 | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2004-08-26 | — | — | WO | claimed |
| US-20040162309-A1 | Methods and compositions related to IRM compounds and toll-like receptor 8 | 3M INNOVATIVE PROPERTIES COMPANY | 2004-08-19 | — | — | US | claimed |
| US-20250152703-A1 | COMPOSITIONS FOR STIMULATION OF MAMMALIAN INNATE IMMUNE RESISTANCE TO PATHOGENS | THE BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 2025-05-15 | — | — | US | disclosed |
| US-12201684-B2 | Compositions for stimulation of mammalian innate immune resistance to pathogens | THE BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2025-01-21 | — | — | US | disclosed |
| US-20240417738-A1 | IMMUNOTHERAPIES FOR THE TREATMENT OF CANCER | OHIO STATE INNOVATION FOUNDATION | 2024-12-19 | — | — | US | disclosed |
| US-20040202720-A1 | Delivery of immune response modifier compounds using metal-containing particulate support materials | 3M INNOVATIVE PROPERTIES COMPANY | 2004-10-14 | — | — | US | disclosed |
| WO-2004071459-A2 | METHODS AND COMPOSITIONS RELATED TO IRM COMPOUNDS AND TOLL-LIKE RECEPTOR 8 | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2004-08-26 | — | — | WO | disclosed |
| US-20040162309-A1 | Methods and compositions related to IRM compounds and toll-like receptor 8 | 3M INNOVATIVE PROPERTIES COMPANY | 2004-08-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040202720-A1 | Delivery of immune response modifier compounds using metal-containing particulate support materials | MIF, IRF3, IRF2BP2 | HTR2A 3595/4885HTR2C 4585/4885HTR2B 3817/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.